157 related articles for article (PubMed ID: 32642666)
1. The impact of host immune cells on the development of neurofibromatosis type 1: The abnormal immune system provides an immune microenvironment for tumorigenesis.
Wei CJ; Gu SC; Ren JY; Gu YH; Xu XW; Chou X; Lian X; Huang X; Li HZ; Gao YS; Gu B; Zan T; Wang ZC; Li QF
Neurooncol Adv; 2019; 1(1):vdz037. PubMed ID: 32642666
[TBL] [Abstract][Full Text] [Related]
2. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
3. Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1.
Rhodes SD; Yang FC
Curr Osteoporos Rep; 2016 Feb; 14(1):10-5. PubMed ID: 26932441
[TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.
Wang S; Liechty B; Patel S; Weber JS; Hollmann TJ; Snuderl M; Karajannis MA
J Neurooncol; 2018 May; 138(1):183-190. PubMed ID: 29427150
[TBL] [Abstract][Full Text] [Related]
5. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway.
Feldkamp MM; Angelov L; Guha A
Surg Neurol; 1999 Feb; 51(2):211-8. PubMed ID: 10029430
[TBL] [Abstract][Full Text] [Related]
6. The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.
Karmakar S; Reilly KM
CNS Oncol; 2017 Jan; 6(1):45-60. PubMed ID: 28001089
[TBL] [Abstract][Full Text] [Related]
7. Emerging therapeutic targets for neurofibromatosis type 1.
Walker JA; Upadhyaya M
Expert Opin Ther Targets; 2018 May; 22(5):419-437. PubMed ID: 29667529
[TBL] [Abstract][Full Text] [Related]
8. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation.
Roth TM; Ramamurthy P; Ebisu F; Lisak RP; Bealmear BM; Barald KF
Glia; 2007 Aug; 55(11):1123-33. PubMed ID: 17597122
[TBL] [Abstract][Full Text] [Related]
9. [Neurofibromatosis von Recklinghausen type 1 (NF1) - clinical picture and molecular-genetics diagnostic].
Petrák B; Bendová Š; Lisý J; Kraus J; Zatrapa T; Glombová M; Zámečník J
Cesk Patol; 2015; 51(1):34-40. PubMed ID: 25671360
[TBL] [Abstract][Full Text] [Related]
10. [Neurofibromatosis type 1 or Von Recklinghausen's disease].
Pinson S; Wolkenstein P
Rev Med Interne; 2005 Mar; 26(3):196-215. PubMed ID: 15777582
[TBL] [Abstract][Full Text] [Related]
11. RNA processing and clinical variability in neurofibromatosis type I (NF1).
Skuse GR; Cappione AJ
Hum Mol Genet; 1997; 6(10):1707-12. PubMed ID: 9300663
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in neurofibromatosis type 1.
Arun D; Gutmann DH
Curr Opin Neurol; 2004 Apr; 17(2):101-5. PubMed ID: 15021234
[TBL] [Abstract][Full Text] [Related]
13. Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.
Yang FC; Ingram DA; Chen S; Zhu Y; Yuan J; Li X; Yang X; Knowles S; Horn W; Li Y; Zhang S; Yang Y; Vakili ST; Yu M; Burns D; Robertson K; Hutchins G; Parada LF; Clapp DW
Cell; 2008 Oct; 135(3):437-48. PubMed ID: 18984156
[TBL] [Abstract][Full Text] [Related]
14. Neurofibromatosis type 1 associated low grade gliomas: A comparison with sporadic low grade gliomas.
Helfferich J; Nijmeijer R; Brouwer OF; Boon M; Fock A; Hoving EW; Meijer L; den Dunnen WF; de Bont ES
Crit Rev Oncol Hematol; 2016 Aug; 104():30-41. PubMed ID: 27263935
[TBL] [Abstract][Full Text] [Related]
15. Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1.
Eisenbarth I; Beyer K; Krone W; Assum G
Am J Hum Genet; 2000 Feb; 66(2):393-401. PubMed ID: 10677298
[TBL] [Abstract][Full Text] [Related]
16. Neurofibromatosis type 1, gastrointestinal stromal tumor, leiomyosarcoma and osteosarcoma: four cases of rare tumors and a review of the literature.
Afşar CU; Kara IO; Kozat BK; Demiryürek H; Duman BB; Doran F
Crit Rev Oncol Hematol; 2013 May; 86(2):191-9. PubMed ID: 23218951
[TBL] [Abstract][Full Text] [Related]
17. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
[TBL] [Abstract][Full Text] [Related]
18. Neurofibromatosis type 1.
North K
Am J Med Genet; 2000; 97(2):119-27. PubMed ID: 11180219
[TBL] [Abstract][Full Text] [Related]
19. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
[TBL] [Abstract][Full Text] [Related]
20. The role of nerve microenvironment for neurofibroma development.
Liao CP; Pradhan S; Chen Z; Patel AJ; Booker RC; Le LQ
Oncotarget; 2016 Sep; 7(38):61500-61508. PubMed ID: 27517146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
